Skip to main content

Immuron Limited (IMRN)

NASDAQ: IMRN · IEX Real-Time Price · USD
3.55
-0.06 (-1.66%)
After-hours:Oct 21, 2021 5:00 PM EDT
3.61
0.01 (0.28%)
At close: Oct 21, 4:00 PM
Market Cap20.90M
Revenue (ttm)1.74M
Net Income (ttm)-2.02M
Shares Out5.68M
EPS (ttm)-1.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume17,123
Open3.65
Previous Close3.60
Day's Range3.60 - 3.73
52-Week Range3.40 - 9.48
Beta1.85
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About IMRN

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive func...

IndustryBiotechnology
Founded1994
CountryAustralia
Stock ExchangeNASDAQ
Ticker SymbolIMRN
Full Company Profile

Financial Performance

In 2020, Immuron's revenue was 2.52 million, an increase of 5.49% compared to the previous year's 2.39 million. Losses were -2.93 million, -37.14% less than in 2019.

Financial numbers in millions AUDFinancial Statements

News

Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19

Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studies were conducted independently by the Hadassah Medical ...

1 week ago - Benzinga

IMM-124E – Demonstrates Antiviral T-Cell Immunity

Key Points

1 week ago - GlobeNewsWire

Immuron Director resignation

MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...

3 weeks ago - GlobeNewsWire

Immuron planned Acquisition of R&D Vaccine Company

MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeuti...

4 weeks ago - GlobeNewsWire

Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutic...

9 months ago - GlobeNewsWire

Immuron Receives AUD $358,280 R&D Tax Concession Refund

MELBOURNE, Australia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics...

10 months ago - GlobeNewsWire

Immuron Travelers’ Diarrhea Market Update

Key Points

1 year ago - GlobeNewsWire

Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering

MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing ora...

1 year ago - GlobeNewsWire

Why Nanocap Biotech Immuron's Stock Is On A 2-Day Run

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) were rallying for the second day in a row Tuesday following an announcement concerning a potential COVID-19 treatment option.

1 year ago - Benzinga

Immuron's stock pulls back but still nearly doubles after stock offering

Shares of Immuron Ltd. IMRN, +56.58% nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered d...

1 year ago - Market Watch

Why Immuron’s New COVID-19 Study Is a Game Changer

Immuron Ltd. (NASDAQ: IMRN) continued its winning streak on Tuesday after the company announced that its IMM-124E has demonstrated neutralizing activity against the severe acute respiratory syndrome cor...

1 year ago - 24/7 Wall Street

Immuron Announces $20.0 Million Registered Direct Offering

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeut...

1 year ago - GlobeNewsWire

Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points

MELBOURNE, Australia, July 21, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeut...

1 year ago - GlobeNewsWire

Can the 800% Gain in Immuron Be Rationalized Very Easily?

The day traders are back at it, chasing stocks on news with very few thoughts about what the fundamentals may be if the good news pans out.

1 year ago - 24/7 Wall Street

Immuron's stock blasts off nearly 10-fold after partner NMRC seeks pre-IND meeting with FDA

The U.S.-listed shares of of Immuron Ltd. IMRN, 1,152.32% skyrocketed nearly 10-fold on massive volume in afternoon trading Tuesday

1 year ago - Market Watch

Immuron's Stock Surges 300% On US Navy Contract

Shares of Australian biopharma IMMURON LTD/S ADR (NASDAQ: IMRN) are on a roll Tuesday on the back of financing deal for one of its pipeline assets.

1 year ago - Benzinga

Immuron Board Relinquish Cash Payment of Fees

MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu...

1 year ago - GlobeNewsWire

Resignation of CEO & Director and cost cutting amidst COVID-19

MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the Comp...

1 year ago - GlobeNewsWire